Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results to be presented at the upcoming American Academy of Ophthalmology annual meeting
Subscribe to our email newsletter
EyeGate Pharma (EyeGate) has completed phase II study of its lead product candidate, EGP-437, for the treatment of anterior uveitis. In the study, EGP-437, a corticosteroid solution specifically designed for iontophoresis, was delivered using the EyeGate II Ocular Drug Delivery System. It is a non-invasive drug delivery technology to treat multiple ocular diseases.
The company has claimed that EyeGate is the first company to complete phase II studies using iontophoresis technology to deliver an active compound into the eye under an investigational new drug (IND) protocol.
Reportedly, the data from the phase II dry eye syndrome study will be presented in a poster session at the American Academy of Ophthalmology (AAO) annual meeting being held from Oct. 23 to 27 in San Francisco.
Stephen From, president and CEO of EyeGate, said: “We are pleased that EyeGate has completed two phase II studies using our iontophoresis technology to deliver EGP-437, one in dry eye patients and one in anterior uveitis patients. These results help demonstrate that drugs delivered by iontophoresis may offer ophthalmologists new treatments for patients.”